Filing Flows

Filing Flows › Companies › Syra Health › Cash flow

Syra Health cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$332K in Q3 2026 · $686K over twelve months

Operating cash flow$332K
Free cash flow+$332K
Cash / net income1.0×

Analysis

In Q3 2026, Syra Health generated $332K of operating cash flow. That is $576K more than in Q3 2025 (−$244K).

Over the twelve months to Sep 30, 2026, operating cash flow was $686K; the largest uses were net borrowing (+) / repaid (−) ($279K); the cash balance rose by $407K.

Operating cash flow was $332K against net income of $345K — 1.0× profit, roughly in line with earnings. The largest differences: deferred revenue −$245K, accrued liabilities +$148K, prepaid and other assets +$70K.

Free cash flow

Syra Health: free cash flow by quarterSyra Health: free cash flow by quarter−$215KQ4 2024$158KQ1 2025−$72KQ2 2025−$244KQ3 2025−$289KQ4 2025$1.4MQ1 2026−$719KQ2 2026$332KQ3 2026
Operating cash flow less capital spending.
Syra Health: operating cash flow against capital spendingSyra Health: operating cash flow against capital spendingOperating cash flowCapital spending−$215K$0Q4 2024$158K$0Q1 2025−$72K$0Q2 2025−$244K$0Q3 2025−$289K$0Q4 2025$1.4M$0Q1 2026−$719K$0Q2 2026$332K$0Q3 2026
Latest (Q3 2026): Operating cash flow $332K, Capital spending $0.

Capital allocation, year by year

Syra Health: where the cash came from (up) and went (down), by fiscal yearSyra Health: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2022: Operating cash flow −$2.2MFY2022: Net borrowing $736KFY2022: Shares issued $2.3MFY2022: Capital spending −$121K$3.1MFY2022FY2023: Operating cash flow −$2.8MFY2023: Net borrowing $519KFY2023: Shares issued $5.3MFY2023: Capital spending −$15K$5.9MFY2023FY2024: Operating cash flow −$2.9MFY2024: Net borrowing −$411KFY2024: Shares issued $2.5MFY2024: Capital spending −$11K$2.5MFY2024FY2025: Operating cash flow −$448KFY2025: Net borrowing −$348KFY2025: Shares issued $15KFY2025: Capital spending −$107$15KFY2025
Over these 4 years operating cash flow totalled −$8.4M; the largest uses were operating cash flow ($8.4M) and net borrowing ($758K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$2.4M
Debtnone
Net cash$2.4M

Syra Health funds itself: free cash flow was $686K over the last twelve months, with $2.4M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Syra Health: sources (+) and uses (−) of cash, Q3 2026Syra Health: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$332KCash drawn (+) / kept (−)−$260KNet borrowing (+) / repaid (−)−$72K
Syra Health: sources (+) and uses (−) of cash, TTM to Q3 2026Syra Health: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$686KCash drawn (+) / kept (−)−$407KNet borrowing (+) / repaid (−)−$279KNot reconciled−$107

From profit to cash

Syra Health: net income to operating cash flow, Q3 2026Syra Health: net income to operating cash flow, Q3 2026Net income$345KDepreciation & amortization$1KStock-based pay$45KReceivables−$47KPayables$16KAccrued liabilities$148KDeferred revenue−$245KPrepaid and other assets$70KOther operating capital$21KOperating cash flow$332K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$332K−$72K—−$260K$332K
Q2 2026−$719K−$80K—$799K−$719K
Q1 2026$1.4M−$54K—−$1.3M$1.4M
Q4 2025−$289K−$73K—$362K−$289K
Q3 2025−$244K−$85K—$329K−$244K
Q2 2025−$72K−$112K—$185K−$72K
Q1 2025$158K−$78K$15K−$95K$158K
Q4 2024−$215K−$87K—$302K−$215K

Syra Health: income statement and cash flow

Syra Health, Q3 2026: revenue $2.6M (+52% year over year), operating margin 11.7%. The chart follows the revenue to costs, profit and cash.

Syra Health: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.